Pragmatic exercise intervention for people with multiple sclerosis (ExIMS trial): study protocol for a randomised controlled trial. 2013

J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
School of Allied Health Professions, University of East Anglia, Norwich, UK. john.saxton@uea.ac.uk

Exercise is an effective intervention for improving function, mobility and health-related quality of life in people with multiple sclerosis (PwMS). Questions remain however, regarding the effectiveness of pragmatic exercise interventions for evoking tangible and sustained increases in physical activity and long-term impact on important health outcomes in PwMS. Furthermore, dose-response relationships between exercise and health outcomes have not previously been reported in PwMS. These issues, and improved knowledge of cost effectiveness, are likely to influence key decisions of health policy makers regarding the implementation of exercise therapy as part of the patient care pathway for PwMS. Hence, the primary aim of this study is to investigate whether a 12-week tapered programme of supervised exercise, incorporating cognitive-behavioural techniques to facilitate sustained behaviour change, is effective for evoking improvements in physical activity and key health outcomes in PwMS over 9 months of follow-up. A total of 120 PwMS will be randomised (1:1) to either a 12-week pragmatic exercise therapy intervention or usual care control group. Participants will be included on the basis of a clinical diagnosis of MS, with an expanded disability status score (EDSS) between 1 and 6.5. Outcome measures, to be assessed before and after the intervention and 6 months later, will include physical activity, clinical and functional measures and health-related quality of life. In addition, the cost effectiveness of the intervention will be evaluated and dose-response relationships between physical activity and the primary/secondary outcomes in those with mild and more severe disease will be explored.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005081 Exercise Therapy A regimen or plan of physical activities designed and prescribed for specific therapeutic goals. Its purpose is to restore normal musculoskeletal function or to reduce pain caused by diseases or injuries. Rehabilitation Exercise,Remedial Exercise,Therapy, Exercise,Exercise Therapies,Exercise, Rehabilitation,Exercise, Remedial,Exercises, Rehabilitation,Exercises, Remedial,Rehabilitation Exercises,Remedial Exercises,Therapies, Exercise
D005260 Female Females
D006304 Health Status The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures. General Health,General Health Level,General Health Status,Level of Health,Overall Health,Overall Health Status,General Health Levels,Health Level,Health Level, General,Health Levels,Health Status, General,Health Status, Overall,Health, General,Health, Overall,Level, General Health,Levels, General Health,Status, General Health,Status, Health,Status, Overall Health
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
December 2014, BMC neurology,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
November 2011, Journal of neurology, neurosurgery, and psychiatry,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
December 2021, BMJ open,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
February 2022, Current oncology (Toronto, Ont.),
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
December 2015, Trials,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
January 2016, Trials,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
April 2014, Homeopathy : the journal of the Faculty of Homeopathy,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
November 2020, BMJ open,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
January 2021, BMJ open,
J M Saxton, and A Carter, and A J Daley, and Nicky Snowdon, and M N Woodroofe, and J Petty, and A Roalfe, and J Tosh, and B Sharrack
October 2017, BMJ open,
Copied contents to your clipboard!